Biograph 55
United States
unknown
unknown
Stage
1
Investors
About
Develops a bispecific antibody immunotherapy (lead program B%%-001) that targets a regulatory B-cell (B-reg) population in solid tumors; the program is also being developed to eliminate plasma cells involved in autoimmune diseases.
Explore Biograph 55's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.